Quince Therapeutics Amends Articles of Incorporation
Ticker: QNCX · Form: 8-K · Filed: 2026-04-09T09:23:02-04:00
Sentiment: neutral
Topics: corporate-governance, amendment
Related Tickers: QNCE
TL;DR
Quince Therapeutics (QNCE) filed an 8-K on 4/9/26 to amend its Articles of Incorporation.
AI Summary
On April 9, 2026, Quince Therapeutics, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation. These amendments, filed under Item 5.03, signify changes to the company's foundational governing documents.
Why It Matters
Amendments to Articles of Incorporation can alter a company's structure, governance, or shareholder rights, potentially impacting its strategic direction and investor relations.
Risk Assessment
Risk Level: low — This filing pertains to administrative changes in corporate governance documents and does not immediately indicate significant financial or operational risks.
Key Players & Entities
- Quince Therapeutics, Inc. (company) — Filer of the 8-K report
- 0001662774 (company) — CIK number for Quince Therapeutics, Inc.
- 2026-04-09 (date) — Filing date of the 8-K report
FAQ
What specific items were amended in Quince Therapeutics' Articles of Incorporation?
The filing indicates amendments under Item 5.03, which covers Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Specific details of the amendments are not provided in the summary but would be found within the referenced exhibits.
What is the CIK number for Quince Therapeutics, Inc.?
The CIK number for Quince Therapeutics, Inc. is 0001662774.
When was this 8-K filing accepted by the SEC?
The 8-K filing was accepted on April 9, 2026, at 09:23:02.
What are the business and mailing addresses for Quince Therapeutics, Inc.?
Both the business and mailing addresses for Quince Therapeutics, Inc. are listed as 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080.
What SIC code is associated with Quince Therapeutics, Inc.?
Quince Therapeutics, Inc. is associated with SIC code 2836, which pertains to Biological Products, (No Diagnostic Substances).
From the Filing
EDGAR Filing Documents for 0001193125-26-149021 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001193125-26-149021 Filing Date 2026-04-09 Accepted 2026-04-09 09:23:02 Documents 12 Period of Report 2026-04-09 Items Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K d115661d8k.htm iXBRL 8-K 29193 2 EX-3.1 d115661dex31.htm EX-3.1 7796 Complete submission text file 0001193125-26-149021.txt 158123 Data Files Seq Description Document Type Size 3 XBRL TAXONOMY EXTENSION SCHEMA qncx-20260409.xsd EX-101.SCH 2850 4 XBRL TAXONOMY EXTENSION LABEL LINKBASE qncx-20260409_lab.xml EX-101.LAB 18736 5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qncx-20260409_pre.xml EX-101.PRE 11706 15 EXTRACTED XBRL INSTANCE DOCUMENT d115661d8k_htm.xml XML 3860 Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717 Quince Therapeutics, Inc. (Filer) CIK : 0001662774 (see all company filings) EIN. : 901024039 | State of Incorp.: CA | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-38890 | Film No.: 26850028 SIC : 2836 Biological Products, (No Diagnostic Substances) (CF Office: 03 Life Sciences)